Abstract: It is intended to provide a kit or a device for the detection of esophageal cancer and a method for detecting esophageal cancer. The present invention provides a kit or a device for the detection of esophageal cancer, comprising nucleic acid(s) capable of specifically binding to miRNA(s) in a sample f a subject, and a method for detecting esophageal cancer, comprising measuring the miRNA in vitro.

Abstract: It is intended to provide a kit or a device for the detection of lung cancer and a method for detecting lung cancer. The present invention provides a kit or a device for the detection of lung cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample from a subject, and a method for detecting lung cancer, comprising measuring the miRNA in vitro.

Abstract: A method of correcting an expression level(s) of a target small RNA(s) for comparative analysis of the expression level(s) in a plurality of samples includes adding at least one kind of standard substance to each of the plurality of samples, extracting nucleic acids from each sample to obtain a nucleic acid sample; measuring the amounts of the target small RNA(s) and the standard substance(s) present in each extracted nucleic acid sample; obtaining a representative value from the measured value(s) of the amount(s) of the standard substance(s) extracted; obtaining the difference or the ratio between a reference value arbitrarily set in connection with the amount(s) of the standard substance(s) extracted and the representative value of the standard substance(s) obtained for each sample; and correcting the expression level(s) of the target small RNA(s).

Abstract: It is intended to provide a kit or a device for the detection of colorectal cancer and a method for detecting colorectal cancer. The present invention provides a kit or a device for the detection of colorectal cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample from a subject, and a method for detecting colorectal cancer, comprising measuring the miRNA in vitro.

Abstract: It is intended to provide a kit or a device for the detection of breast cancer and a method for detecting breast cancer. The present invention provides a kit or a device for the detection of breast cancer, comprising nucleic acid(s) capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting breast cancer, comprising measuring the miRNA in vitro.

Abstract: This invention relates to a kit or a device for the detection of stomach cancer and a method for detecting stomach cancer, and provides a kit or a device for the detection of stomach cancer, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting stomach cancer, comprising measuring the miRNA(s) in vitro.

Abstract: It is intended to provide a kit or device for the detection of liver cancer and a method for detecting liver cancer. The present invention relates to a kit or device for the detection of liver cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting liver cancer, comprising measuring the miRNA in vitro.

Abstract: This invention provides a kit or a device for the detection of pancreatic cancer, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting pancreatic cancer, comprising measuring the miRNA(s) in vitro.

Abstract: This invention provides a kit or a device for the detection of pancreatic cancer, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting pancreatic cancer, comprising measuring the miRNA(s) in vitro.

Abstract: The present invention provides a kit or device for the detection of malignant brain tumor, and a method for detecting malignant brain tumor. The present invention relates to a kit or device for the detection of malignant brain tumor, comprising nucleic acid(s) capable of specifically binding to predetermined miRNA(s) in a sample of a subject, and a method for detecting malignant brain tumor, comprising measuring the miRNA(s) in vitro.

Abstract: A method of evaluating quality of miRNA derived from a body fluid sample includes a measuring step; comparing a measured value(s) of the abundance(s) of the one or more reference miRNAs in a body fluid sample or a representative value thereof to a measured value(s) of the abundance(s) of the one or more reference miRNAs in a standard body fluid sample or a representative value thereof, to obtain a difference(s) or a ratio(s) of the measured value(s) of the abundance(s) of the one or more reference miRNAs or the representative value thereof between the body fluid sample and the standard body fluid sample; and judging the quality of the miRNA derived from the body fluid sample based on the difference(s) or the ratio(s) of the measured value(s) of the abundance(s) of the one or more reference miRNAs or the representative value thereof obtained in the comparing step.

Abstract: This invention relates to a composition and a method for prediction of a response to Trastuzumab therapy in a breast cancer patient, and more specifically, a composition, a kit, a DNA chip, and a method for predicting a response to Trastuzumab therapy by using polynucleotides each comprising a nucleotide sequence represented by any of SEQ ID NOs: 1 to 9, 11 to 19, and 21 to 23 in the Sequence Listing or a nucleotide sequence derived therefrom by substitution of u with t, mutants thereof, derivatives thereof, or fragments thereof comprising at least 16 continuous nucleotides, or a polynucleotide comprising a complementary sequence thereof, and using an increase or decrease in Her2 protein expression level as an indicator.

Abstract: A method of correcting an expression level(s) of a target small RNA(s) for comparative analysis of the expression level(s) in a plurality of samples includes adding at least one kind of standard substance to each of the plurality of samples, extracting nucleic acids from each sample to obtain a nucleic acid sample; measuring the amounts of the target small RNA(s) and the standard substance(s) present in each extracted nucleic acid sample; obtaining a representative value from the measured value(s) of the amount(s) of the standard substance(s) extracted; obtaining the difference or the ratio between a reference value arbitrarily set in connection with the amount(s) of the standard substance(s) extracted and the representative value of the standard substance(s) obtained for each sample; and correcting the expression level(s) of the target small RNA(s).

Abstract: This invention provides a kit or a device for the detection of pancreatic cancer, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting pancreatic cancer, comprising measuring the miRNA(s) in vitro.

Abstract: In a method for comparative analysis, the expression levels of the target miRNAs in each body fluid sample are corrected using the expression level(s) of a correcting endogenous miRNA(s) that is/are simultaneously measured with the expression levels of the target miRNAs in the sample. As the correcting endogenous miRNA(s), one or more miRNAs selected from specific 10 kinds of correcting endogenous miRNAs is/are used. Comparative analysis of target miRNAs among body fluid samples can be carried out more accurately than by conventional techniques.

Abstract: It is intended to provide a kit or device for the detection of liver cancer and a method for detecting liver cancer. The present invention relates to a kit or device for the detection of liver cancer, comprising a nucleic acid capable of specifically binding to miRNA in a sample of a subject, and a method for detecting liver cancer, comprising measuring the miRNA in vitro.

Abstract: It is intended to provide a kit or a device for the detection of colorectal cancer and a method for detecting colorectal cancer. The present invention provides a kit or a device for the detection of colorectal cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample from a subject, and a method for detecting colorectal cancer, comprising measuring the miRNA in vitro.

Abstract: It is intended to provide a kit or a device for the detection of lung cancer and a method for detecting lung cancer. The present invention provides a kit or a device for the detection of lung cancer, comprising a nucleic acid capable of specifically binding to a miRNA in a sample from a subject, and a method for detecting lung cancer, comprising measuring the miRNA in vitro.

Abstract: It is intended to provide a kit or a device for the detection of esophageal cancer and a method for detecting esophageal cancer. The present invention provides a kit or a device for the detection of esophageal cancer, comprising nucleic acid(s) capable of specifically binding to miRNA(s) in a sample f a subject, and a method for detecting esophageal cancer, comprising measuring the miRNA in vitro.

Abstract: It is intended to provide a kit or a device for the detection of breast cancer and a method for detecting breast cancer. The present invention provides a kit or a device for the detection of breast cancer, comprising nucleic acid(s) capable of specifically binding to a miRNA in a sample of a subject, and a method for detecting breast cancer, comprising measuring the miRNA in vitro.